Related Experiment Video
Updated: Aug 7, 2026
05:22
Iris Fixation via External Pentagram Suturing
Published on: May 5, 2022
Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo
Louise A Mawn1, Erin Moore Shriver2, Madhura Tamhankar3
1Department of Ophthalmology, Vanderbilt University Medical Center, Vanderbilt Eye Institute, Nashville, TN, USA.
Clinical Ophthalmology (Auckland, N.Z.)
|July 28, 2026
Summary
This study analyzed real-world data on thyroid eye disease (TED) patients treated with teprotumumab. Findings show high disease burden at baseline and prompt treatment initiation, with good adherence to dosing regimens.
Area of Science:
- Ophthalmology
- Endocrinology
- Rheumatology
Background:
- Thyroid eye disease (TED) is a serious autoimmune condition affecting the eyes.
- Teprotumumab is a novel biologic treatment for TED.
- Understanding real-world treatment patterns is crucial for optimizing patient care.
Purpose of the Study:
- To describe patient characteristics and teprotumumab treatment patterns in a large cohort with TED.
- To analyze real-world data on teprotumumab adoption and adherence.
- To evaluate treatment patterns based on disease duration.
Main Methods:
- Observational, retrospective cohort study using linked clinical and claims data (IRIS Registry and Komodo Health Research Dataset, 2019-2024).
- Included adult patients with confirmed TED who initiated teprotumumab post-approval.
- Examined demographics, baseline disease burden (CAS, proptosis, diplopia), and infusion patterns.
Main Results:
- 2,886 patients included; mean age 59 years, 77% female.
- High baseline disease burden observed (e.g., 45% proptosis, 91% active disease if CAS recorded).
- 70% initiated teprotumumab within 12 months of diagnosis; 65% completed 8 infusions, with 10% receiving retreatment.
Conclusions:
- Real-world analysis shows significant baseline TED burden and timely teprotumumab initiation.
- Findings indicate adherence to FDA-indicated dosing and evolving clinical practice.
- Supports ongoing research into teprotumumab's long-term impact on TED natural history.
